{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ulcerative-colitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"04f00df3-2de5-5c61-bb95-25edda5f885b","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field e9f2628b-2a9a-4544-bb0a-730a95259ca3 --><h2>Changes</h2><!-- end field e9f2628b-2a9a-4544-bb0a-730a95259ca3 -->","summary":null,"htmlStringContent":"<!-- begin item e73cfa5f-6592-4990-8e40-52aafd770acf --><!-- begin field d067b954-1706-45df-bfe9-bbfd71796f05 --><p><strong>April 2020</strong> — minor update. New management scenario created to provide information regarding COVID-19.</p><p><strong>March to April 2019</strong> — reviewed. A literature search was conducted in March 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone significant restructuring. The recommendations on the diagnosis and management of confirmed ulcerative colitis have been amended in line with current evidence. The sections on specialist investigations and management have been updated and expanded. The Prescribing information section has been deleted and links made to other relevant CKS topics.</p><!-- end field d067b954-1706-45df-bfe9-bbfd71796f05 --><!-- end item e73cfa5f-6592-4990-8e40-52aafd770acf -->","topic":{"id":"34aee656-b482-5065-8656-44c487e4e347","topicId":"6a63bd87-53c1-487d-8426-773cffdb4c43","topicName":"Ulcerative colitis","slug":"ulcerative-colitis","lastRevised":"Last revised in April 2020","chapters":[{"id":"8ec19c69-a796-514b-a267-91bd57a12fe3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dc4de3c1-9955-536e-9789-a900261d2189","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"04875f8c-29b3-5d60-8e5c-06930138cfc4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04f00df3-2de5-5c61-bb95-25edda5f885b","slug":"changes","fullItemName":"Changes"},{"id":"12402ddb-2eb9-589e-a1c3-24d50e2538f8","slug":"update","fullItemName":"Update"}]},{"id":"2c186889-f3c1-5094-b0ce-0b9a81f46d61","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"36a3da73-b00f-5ee2-bfd9-33293a674904","slug":"goals","fullItemName":"Goals"},{"id":"5c86e0bc-3476-59dd-b120-519602968645","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3ab8e65e-aac9-54a1-abb3-9185c76c6004","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0efa89a1-51f7-59ff-95ce-94faac48f8a5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a2b17331-6cfc-56eb-84c5-433f78f4364c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"01a70081-193a-5d75-92fb-45f84ee7b317","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"87cfff6e-6028-5fda-aee6-4473268cac77","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"116a07eb-6832-5d49-aa1d-497f7c0684a9","slug":"definition","fullItemName":"Definition"},{"id":"fef2143b-1809-58f3-bdf9-0d73710d89ae","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9c9a2e21-7e98-5876-945d-ec18ebfaee62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5102ad12-cd60-5939-ad9a-00d4dafca9b0","slug":"complications","fullItemName":"Complications"},{"id":"488ac85b-91d2-5298-9127-69ae212ceeac","slug":"extra-intestinal-manifestations","fullItemName":"Extra-intestinal manifestations"},{"id":"9ff94ba6-78d6-5ed0-9cda-f234b24236d7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2149059a-c90f-50e5-9fa2-227a488d2004","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"40b81845-1ebc-55b2-b825-05a3d62e3cc4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"0102b680-c790-5c87-aaec-ea332f5fc9b2","slug":"investigations","fullItemName":"Investigations"},{"id":"2ea841c6-272f-5b4b-a165-499ec0228439","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"468c6dcc-e9f2-5154-9f2b-30d7dafb7415","fullItemName":"Management","slug":"management","subChapters":[{"id":"6a9b8b90-a418-5e1b-9442-ac55ee36430f","slug":"suspected-ulcerative-colitis","fullItemName":"Scenario: Suspected ulcerative colitis"},{"id":"6d8002d3-29fe-5bfd-ba03-7ce0173636e4","slug":"confirmed-ulcerative-colitis","fullItemName":"Scenario: Confirmed ulcerative colitis"},{"id":"56868b16-5233-5bb8-9412-d2d9bfafe8d9","slug":"fertility-pregnancy-breastfeeding-with-ulcerative-colitis","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis"},{"id":"7708c2de-0c02-5b83-a354-70788b3dc297","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"010b277d-6575-5cdc-b995-6fc7d89fb745","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a8ed7157-985a-58a5-b567-571fa748a73b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1164542-c6ec-5b63-bfee-efc59657c778","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"568370d3-2e5b-55a4-ae50-2eeeb5ca3234","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"df1aecf8-eeb0-5069-965e-21ccf0690af8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"889198a1-b809-54b2-b803-3ee02e6f45af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a290d39a-e351-5dec-9607-943a59e60b2e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"916d81a4-ae1e-529e-936f-183b4514ba9f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"04875f8c-29b3-5d60-8e5c-06930138cfc4","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"aeb8cc1d-3ab3-5d79-94ca-9e271e490cba","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field aa44c845-71f2-4365-adbc-57ba08e005d5 --><h3>Previous changes</h3><!-- end field aa44c845-71f2-4365-adbc-57ba08e005d5 -->","summary":null,"htmlStringContent":"<!-- begin item b2d393f9-7e19-41a1-9a7e-e8410ed5227a --><!-- begin field 47b4ffb1-5101-4987-87a4-3995ffaa1097 --><p><strong>July 2015 </strong>— minor update. Following an update to the manufacturers' Summaries of Product Characteristics (SPCs), cardiac hypersensitivity has been added as a rare adverse effect of mesalazine. In addition, there is information on the presence of intact tablets in stools (2015). An interaction between amlodipine and tacrolimus has been added to the topic (2015).</p><p><strong>August 2014 </strong>— reviewed. A literature search was conducted in July 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. This topic has been updated in line with the National Institute for Health and Care Excellence (NICE) guideline, <em>Ulcerative Colitis. Management in adults, children and young people </em>(2013).</p><p><strong>May 2011 </strong>— minor update to the text to reflect guidance issued by the British Society of Gastroenterology (BSG). Issued in June 2011.</p><p><strong>April 2011 </strong>— minor update. The National Institute for Health and Care Excellence (NICE) has issued guidance on colonoscopic surveillance of people with ulcerative colitis. Issued in June 2011.</p><p><strong>February 2011 </strong>— minor update. Typical doses of aminosalicylates for use in children added to the <em>Prescribing information </em>section. Issued in February 2011.</p><p><strong>January 2011 </strong>— minor update to the text regarding the doses of Asacol MR<sup>®</sup>. Issued in February 2011.</p><p><strong>September 2010 </strong>— minor update to the text regarding the mode of action of Mezavant XL<sup>®</sup>.</p><p><strong>February to June 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 47b4ffb1-5101-4987-87a4-3995ffaa1097 --><!-- end item b2d393f9-7e19-41a1-9a7e-e8410ed5227a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}